Chugai Seiyaku Kabushiki Kaisha

F. Hoffmann-la Roche Ag

Satoshi Niizuma

Takeshi Murata

Masao Tsukazaki

Hatsuo Kawada

Yoshito Nakanishi

Kihito Hada

Hitomi Suda

Hideaki Shimada

Sousuke Hara

Hiroshi Tanaka

Nobuo Shimma

Kazuo Hattori

Takehiro Okada

Hiroki Nishii

Hiroshi Fukuda

Masahiro Sakaitani

Jun Ohwada

Toshiyuki Tsukaguchi

Hirosato Ebiike

Toshihiro Aoki

Toshiyuki Mio

Masami Kochi

Miyako Masubuchi

Osamu Kondoh

Kimitaka Nakama

Miyuki Yoshida

Kohei Koyama

Natsuki Kobayashi

Takashi Chiba

Hiroyuki Shimamura

Kenji Tatsuno

Hiroyuki Eda

Aiko Suge

An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Aris optionally substituted Carylene or 5- to 10-membered heteroarylene, and Aris optionally substituted Caryl or 5- to 10-membered heteroaryl. Rand Rare defined as described in the specification.

Aminopyrazole derivatives

The present invention relates to quinazolinone and isoquinolinone derivatives represented by formula (I) or pharmaceutically acceptable salts thereof. 

Quinazolinone and isoquinolinone derivative

The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof. 

Benzamide derivative

The present invention relates to quinazolinedione derivatives represented by formula (I) or pharmaceutically acceptable salts thereof. 

Quinazolinedione derivative

The present invention provides: a compound represented by the following formula (I): [wherein Yand Yrepresent a hydrogen atom or a halogen atom; either one of Yand Yrepresents &#x2014;NRR, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; Rrepresents a hydrogen atom, or a Calkyl group that may be substituted; and Rrepresents a Calkyl group that is substituted with one or more substituents, &#x2014;COOR, &#x2014;COR, &#x2014;COSR, &#x2014;CONRR, &#x2014;NRR, or &#x2014;C&#x2550;NRR; or Rand R, together with a nitrogen atom to which they are bonded, may form a 4- to 10-membered hetero ring containing at least one nitrogen atom (wherein the hetero ring may be substituted with one or more substituents selected from Group C)], a prodrug thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical, a pharmaceutical composition, or the like, which comprises the compound.

1-(2H)-isoquinolone derivative

The present invention provides a compound having high antitumor activity, which is useful for therapeutic and preventive agents effective for proliferative diseases such as cancer; a production method thereof; an intermediate compound useful for such production; and a pharmaceutical composition comprising such a compound. The present invention provides a compound represented by the formula (1): wherein X represents an aryl group or heteroaryl group which may be substituted, Cy represents a 4- to 7-membered monocyclic heterocyclic ring or a 8- to 10-membered condensed heterocyclic ring which may be substituted, and Z represents O, S, or NRa; or a prodrug thereof; or a pharmaceutically acceptable salt thereof; and a pharmaceutical and a pharmaceutical composition which comprise the compound.

This invention relates to novel processes for the preparation of compounds of the formula [1], wherein R1, R2, R3 and R4 are as defined in the claims and description as well as pharmaceutically acceptable salts thereof. The compounds of the formula [1] are hexacyclic compounds having potent anti-tumor activity. 

Process for the preparation of hexacyclic compounds

The present invention relates to hexacyclic compound of the formula [1], wherein Z, Rand Rare as identified therein, and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of cell proliferative disorders.

Hexacyclic compounds and their therapeutic use

Hexacyclic compounds

Growing community of inventors

Kanagawa, Japan

Satoshi Niizuma